The global biologics market size is expected to reach around US$ 719.84 billion by 2030 from US$ 366.43 billion in 2021 and is expected to grow at an impressive double-digit rate of 7.8% from 2022 to 2030.
The study includes drivers and restraints of this market. The study provides an analysis of the global biologics market for the period 2017-2030, wherein 2022 to 2030 is the forecast period and 2021 is considered as the base year.
Report Highlights:
- Based on the source, the microbial segment dominated the global biologics market in 2020 with largest market share. The large number of biological medications is prepared with the help of microbial.
- On the basis of product, the monoclonal antibodies segment holds the largest market share the global biologics market in 2020. The use of monoclonal antibodies in the management and control of disorders such as cancer can be linked to the causes of various disorders. It can also be used to target diseased cells while causing no harm to good cells of the human body.
- Based on the disease, the oncology segment dominated the global biologics market in 2020 with largest market share. This is attributed to the rising prevalence of cancer around the globe, which creating demand for biological drugs on large scale.
- North America is the largest segment for biologics market in terms of region. This is due to an increasing number of biology and technological businesses, the existence of major players in pharmaceutical sector, and the growing prevalence of chronic illness occurrences.
- Asia-Pacific region is the fastest growing region in the biologics market. This is attributed to an increase in the number of diabetes and cancer patients, government initiatives for promotion of biologics, and rise in overall healthcare costs.
Our Free Sample Reports Includes:
- In-depth Industry Analysis, Introduction, Overview, and COVID-19 Pandemic Outbreak.
- Impact Analysis 180+ Pages Research Report (Including latest research).
- Provide chapter-wise guidance on request 2022 Updated Regional Analysis with Graphical Representation of Trends, Size, & Share, Includes Updated List of figures and tables.
- Updated Report Includes Major Market Players with their Sales Volume, Business Strategy and Revenue Analysis by using Precedence Research methodology.
Download Free Sample Copy Here (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1638
Future of Biologics Market
The expansion of the biologics market is likely to be boosted by an increase in the incidence of chronic diseases, the loss of patent extensions for branded pharmaceuticals, and the growing availability of advanced diagnostics. Furthermore, market growth is expected to be fueled by advancements in biologics manufacturing technology. However, the market is hampered by the difficulties of manufacturing biologic pharmaceuticals and the processes needed in maintenance, such as preventing environmental contamination and maintaining refrigeration processes, among other things. The rise in demand for improved diagnostics for therapeutic purposes, as well as the expiration of branded medicine patent extensions, gives opportunities for the worldwide biologics market to flourish.
COVID-19 Impact Analysis:
- Due to prevalence of populations with high risk to the COVID-19 pandemic, regulators are more willing to allow manufacturing of micro molecule medications to continue than in the past.
- The healthcare sector is implementing strong plans to reach the goal, which entails ongoing biological drugs and medicines manufacturing, hence strengthening the biologics manufacturing industry.
Key Developments in the Marketplace:
- In August 2021, Moderna Inc. stated that it had completed the rolling application process to the FDA for full licensing of the Moderna COVID-19 vaccine for active vaccination to prevent COVID-19 in people aged 18 and higher.
- In August 2021, Pfizer Inc. and BioNTech SE announced that they have begun a supplemental Biologics License Application with the FDA to get approval for a booster dosage of COMIRNATY to prevent COVID-19 in patients aged 16 and up.
- Biocon Biologics is in talks with ADQ, the Abu Dhabi government’s wealth fund, to advance financing as India’s largest biosimilar maker grows its production to generate value for stakeholders ahead of an expected IPO.
Research Methodology
A unique research methodology has been utilized to conduct comprehensive research on the growth of the global biologics market and arrive at conclusions on the future growth prospects of the market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the draw conclusions. Secondary sources referred to by analysts during the production of the global market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of our study on the market as a primary source.
These primary and secondary sources provided exclusive information during interviews, which serves as a validation from mattress topper industry leaders. Access to an extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global biologics market with accuracy. The study also uses the top-down approach to assess the numbers for each segment and the bottom-up approach to counter-validate them. This has helped to estimates the future prospects of the global market more reliable and accurate.
Why should you invest in this report?
If you are aiming to enter the global biologics market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for biologics are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030, so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Some of the prominent players in the global biologics market include:
- Eli Lilly & Company
- Samsung Biologics
- F Hoffman La Roche
- Celltrion Addgene
- Amgen
- Abbvie Inc.
- Sanofi
- Pfizer Inc.
- Merck & Co. Inc
- Novo Nordisk A/S
Market Segmentations
By Source
- Microbial
- Mammalian
- Others
By Product
- MABs
- Vaccines
- Hormones
- Therapeutic Enzymes
- Recombinant Proteins
- Antisense, RNAi & Molecular Therapy
- Blood Factors and Anticoagulants
- Allergenic extracts
- Human Cells and Tissues
- Proteins
- Gene Therapies
- Cellular Therapies
- Others
By Disease
- Oncology
- Immunological Disorders
- Cardiovascular Disorders
- Hematological Disorders
- Others
By Manufacturing
- Outsourced
- In-house
By Route of Administration
- Oral
- Others (IV and IP)
By Drug Classification
- Branded Drugs
- Generic Drugs
By Mode of Purchase
- Prescription Drugs
- Over-The-Counter (OTC) Drugs
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Analysis:
The geographical analysis of the global biologics market has been done for North America, Europe, Asia-Pacific, and the Rest of the World.
The North American Market is again segmented into the US, Canada, and Mexico. Coming to the European Market, it can be segmented further into the UK, Germany, France, Italy, Spain, and the rest. Coming to the Asia-Pacific, the global biologics Market is segmented into China, India, Japan, and Rest of Asia Pacific. Among others, the market is segmented into the Middle East and Africa, (GCC, North Africa, South Africa and Rest of the Middle East & Africa).
Key Questions Answered by the Report:
- What will be the size of the global biologics market in 2030?
- What is the expected CAGR for the biologics market between 2021 and 2030?
- Which are the top players active in this global market?
- What are the key drivers of this global market?
- How will the market situation change in the coming years?
- Which region held the highest market share in this global market?
- What are the common business tactics adopted by players?
- What is the growth outlook of the global biologics market?
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Biologics Market, By Source
7.1. Biologics Market, by Source, 2022-2030
7.1.1. Microbial
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Mammalian
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Other
7.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Biologics Market, By Product
8.1. Biologics Market, by Product, 2022-2030
8.1.1. MABs
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Vaccines
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Hormones
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Therapeutic Enzymes
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Recombinant Proteins
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Antisense, RNAi & Molecular Therapy
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Blood Factors and Anticoagulants
8.1.7.1. Market Revenue and Forecast (2017-2030)
8.1.8. Allergenic extracts
8.1.8.1. Market Revenue and Forecast (2017-2030)
8.1.9. Cellular Therapies
8.1.9.1. Market Revenue and Forecast (2017-2030)
8.1.10. Gene Therapies
8.1.10.1. Market Revenue and Forecast (2017-2030)
8.1.11. Proteins
8.1.11.1. Market Revenue and Forecast (2017-2030)
8.1.12. Human Cells and Tissues
8.1.12.1. Market Revenue and Forecast (2017-2030)
8.1.13. Others
8.1.13.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Biologics Market, By Disease
9.1. Biologics Market, by Disease, 2022-2030
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Immunological Disorders
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Cardiovascular Disorders
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Hematological Disorders
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Biologics Market, By Manufacturing
10.1. Biologics Market, by Manufacturing, 2022-2030
10.1.1. Outsourced
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. In-house
10.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Biologics Market, By Route of Administration
11.1. Biologics Market, by Route of Administration, 2022-2030
11.1.1. Oral
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Others (IV and IP)
11.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Biologics Market, By Drug Classification
12.1. Biologics Market, by Drug Classification, 2022-2030
12.1.1. Branded Drugs
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Generic Drugs
12.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Biologics Market, By Mode of Purchase
13.1. Biologics Market, by Mode of Purchase, 2022-2030
13.1.1. Prescription Drugs
13.1.1.1. Market Revenue and Forecast (2017-2030)
13.1.2. Over-The-Counter (OTC) Drugs
13.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 14. Global Biologics Market, Regional Estimates and Trend Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Source (2017-2030)
14.1.2. Market Revenue and Forecast, by Product (2017-2030)
14.1.3. Market Revenue and Forecast, by Disease (2017-2030)
14.1.4. Market Revenue and Forecast, by Manufacturing (2017-2030)
14.1.5. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.1.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.1.7. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.1.8. U.S.
14.1.8.1. Market Revenue and Forecast, by Source (2017-2030)
14.1.8.2. Market Revenue and Forecast, by Product (2017-2030)
14.1.8.3. Market Revenue and Forecast, by Disease (2017-2030)
14.1.8.4. Market Revenue and Forecast, by Manufacturing (2017-2030)
14.1.8.5. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.1.8.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.1.8.7. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Source (2017-2030)
14.1.9.2. Market Revenue and Forecast, by Product (2017-2030)
14.1.9.3. Market Revenue and Forecast, by Disease (2017-2030)
14.1.9.4. Market Revenue and Forecast, by Manufacturing (2017-2030)
14.1.9.5. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.1.9.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.1.9.7. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2. Europe
14.2.1. Market Revenue and Forecast, by Source (2017-2030)
14.2.2. Market Revenue and Forecast, by Product (2017-2030)
14.2.3. Market Revenue and Forecast, by Disease (2017-2030)
14.2.4. Market Revenue and Forecast, by Manufacturing (2017-2030)
14.2.5. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.7. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Source (2017-2030)
14.2.8.2. Market Revenue and Forecast, by Product (2017-2030)
14.2.8.3. Market Revenue and Forecast, by Disease (2017-2030)
14.2.8.4. Market Revenue and Forecast, by Manufacturing (2017-2030)
14.2.8.5. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.8.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.8.7. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.9. Germany
14.2.9.1. Market Revenue and Forecast, by Source (2017-2030)
14.2.9.2. Market Revenue and Forecast, by Product (2017-2030)
14.2.9.3. Market Revenue and Forecast, by Disease (2017-2030)
14.2.9.4. Market Revenue and Forecast, by Manufacturing (2017-2030)
14.2.9.5. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.9.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.9.7. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.10. France
14.2.10.1. Market Revenue and Forecast, by Source (2017-2030)
14.2.10.2. Market Revenue and Forecast, by Product (2017-2030)
14.2.10.3. Market Revenue and Forecast, by Disease (2017-2030)
14.2.10.4. Market Revenue and Forecast, by Manufacturing (2017-2030)
14.2.10.5. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.10.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.10.7. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.11. Rest of Europe
14.2.11.1. Market Revenue and Forecast, by Source (2017-2030)
14.2.11.2. Market Revenue and Forecast, by Product (2017-2030)
14.2.11.3. Market Revenue and Forecast, by Disease (2017-2030)
14.2.11.4. Market Revenue and Forecast, by Manufacturing (2017-2030)
14.2.11.5. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.11.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.11.7. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Source (2017-2030)
14.3.2. Market Revenue and Forecast, by Product (2017-2030)
14.3.3. Market Revenue and Forecast, by Disease (2017-2030)
14.3.4. Market Revenue and Forecast, by Manufacturing (2017-2030)
14.3.5. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.7. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.8. India
14.3.8.1. Market Revenue and Forecast, by Source (2017-2030)
14.3.8.2. Market Revenue and Forecast, by Product (2017-2030)
14.3.8.3. Market Revenue and Forecast, by Disease (2017-2030)
14.3.8.4. Market Revenue and Forecast, by Manufacturing (2017-2030)
14.3.8.5. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.8.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.8.7. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.9. China
14.3.9.1. Market Revenue and Forecast, by Source (2017-2030)
14.3.9.2. Market Revenue and Forecast, by Product (2017-2030)
14.3.9.3. Market Revenue and Forecast, by Disease (2017-2030)
14.3.9.4. Market Revenue and Forecast, by Manufacturing (2017-2030)
14.3.9.5. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.9.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.9.7. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.10. Japan
14.3.10.1. Market Revenue and Forecast, by Source (2017-2030)
14.3.10.2. Market Revenue and Forecast, by Product (2017-2030)
14.3.10.3. Market Revenue and Forecast, by Disease (2017-2030)
14.3.10.4. Market Revenue and Forecast, by Manufacturing (2017-2030)
14.3.10.5. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.10.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.10.7. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.11. Rest of APAC
14.3.11.1. Market Revenue and Forecast, by Source (2017-2030)
14.3.11.2. Market Revenue and Forecast, by Product (2017-2030)
14.3.11.3. Market Revenue and Forecast, by Disease (2017-2030)
14.3.11.4. Market Revenue and Forecast, by Manufacturing (2017-2030)
14.3.11.5. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.11.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.11.7. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Source (2017-2030)
14.4.2. Market Revenue and Forecast, by Product (2017-2030)
14.4.3. Market Revenue and Forecast, by Disease (2017-2030)
14.4.4. Market Revenue and Forecast, by Manufacturing (2017-2030)
14.4.5. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.7. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.8. GCC
14.4.8.1. Market Revenue and Forecast, by Source (2017-2030)
14.4.8.2. Market Revenue and Forecast, by Product (2017-2030)
14.4.8.3. Market Revenue and Forecast, by Disease (2017-2030)
14.4.8.4. Market Revenue and Forecast, by Manufacturing (2017-2030)
14.4.8.5. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.8.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.8.7. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.9. North Africa
14.4.9.1. Market Revenue and Forecast, by Source (2017-2030)
14.4.9.2. Market Revenue and Forecast, by Product (2017-2030)
14.4.9.3. Market Revenue and Forecast, by Disease (2017-2030)
14.4.9.4. Market Revenue and Forecast, by Manufacturing (2017-2030)
14.4.9.5. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.9.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.9.7. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.10. South Africa
14.4.10.1. Market Revenue and Forecast, by Source (2017-2030)
14.4.10.2. Market Revenue and Forecast, by Product (2017-2030)
14.4.10.3. Market Revenue and Forecast, by Disease (2017-2030)
14.4.10.4. Market Revenue and Forecast, by Manufacturing (2017-2030)
14.4.10.5. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.10.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.10.7. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.11. Rest of MEA
14.4.11.1. Market Revenue and Forecast, by Source (2017-2030)
14.4.11.2. Market Revenue and Forecast, by Product (2017-2030)
14.4.11.3. Market Revenue and Forecast, by Disease (2017-2030)
14.4.11.4. Market Revenue and Forecast, by Manufacturing (2017-2030)
14.4.11.5. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.11.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.11.7. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Source (2017-2030)
14.5.2. Market Revenue and Forecast, by Product (2017-2030)
14.5.3. Market Revenue and Forecast, by Disease (2017-2030)
14.5.4. Market Revenue and Forecast, by Manufacturing (2017-2030)
14.5.5. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.5.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.5.7. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.5.8. Brazil
14.5.8.1. Market Revenue and Forecast, by Source (2017-2030)
14.5.8.2. Market Revenue and Forecast, by Product (2017-2030)
14.5.8.3. Market Revenue and Forecast, by Disease (2017-2030)
14.5.8.4. Market Revenue and Forecast, by Manufacturing (2017-2030)
14.5.8.5. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.5.8.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.5.8.7. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Source (2017-2030)
14.5.9.2. Market Revenue and Forecast, by Product (2017-2030)
14.5.9.3. Market Revenue and Forecast, by Disease (2017-2030)
14.5.9.4. Market Revenue and Forecast, by Manufacturing (2017-2030)
14.5.9.5. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.5.9.6. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.5.9.7. Market Revenue and Forecast, by Drug Classification (2017-2030)
Chapter 15. Company Profiles
15.1. Eli Lilly & Company
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Samsung Biologics
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. F Hoffman La Roche
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Celltrion Addgene
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Amgen
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Abbvie Inc.
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Sanofi
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Pfizer Inc.
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Merck & Co. Inc
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Novo Nordisk A/S
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
Chapter 16. Research Methodology
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
Chapter 17. Appendix
17.1. About Us
17.2. Glossary of Terms
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1638
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
0 Comments